Targeted therapy plus radiation for HER2-mutant lung cancer
This trial tests a new targeted therapy combined with radiation for people with HER2-mutated lung cancer that is progressing only in a few spots. It aims to see if this combination can help keep the cancer under control and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer with a HER2 mutation, and your cancer has progressed in only 1-5 spots (outside the brain) while on your current treatment.
- You have had at least one line of platinum-based chemotherapy (like carboplatin or cisplatin).
- Your doctor expects you to live at least 3 more months and you feel well enough to do light activities (ECOG 0-1).
- Your lung and heart function are good, and your blood counts and organ function meet basic safety levels.
- You do not have certain other gene changes (like EGFR, ALK, ROS1, RET, MET, or KRAS G12C), active brain metastases, or uncontrolled heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two newer drugs (trastuzumab rezetecan and ivonescimab) for advanced non-small cell lung cancer whose cancer cells have a specific HER2 gene change. The trial includes two groups: people who have already tried one round of treatment, and people newly diagnosed who haven't had treatment yet.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests a targeted drug called trastuzumab deruxtecan in people with advanced non-small cell lung cancer that has high levels of a protein called HER2. It may be an option if your cancer has grown after at least one prior treatment.
This trial is testing a combination of two drugs (adebrelimab and trastuzumab rezetecan) for people with stage III lung cancer that has a HER2 alteration. The tumor must be unresectable (not removable by surgery). Participants must not have had prior systemic treatment for their lung cancer. They need to have measurable disease and be in generally good health.
This trial tests a combination of an EGFR inhibitor pill and an intravenous antibody drug conjugate for people with advanced non-small cell lung cancer who have both an EGFR mutation and a HER2 alteration (mutation, amplification, or protein expression). The goal is to see if this combination works better than standard treatments.
This study tests a new drug (trastuzumab rezetecan) for advanced solid tumors that have a protein called HER2 on their surface. The drug combines an antibody that targets HER2 with a chemotherapy component. It's designed for cancers that have grown despite prior treatment or have no good alternatives.
Hear when a new HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.